Moderna Inc
MRNA27.820USD
+0.215+0.78%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
10.82BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Moderna Inc Unternehmen
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Unternehmensinformationen
BörsenkürzelMRNA
Name des UnternehmensModerna Inc
IPO-datumDec 07, 2018
CEOMr. Stephane Bancel
Anzahl der mitarbeiter5800
WertpapierartOrdinary Share
GeschäftsjahresendeDec 07
Addresse325 Binney Street
StadtCAMBRIDGE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02142
Telefon16177146500
Websitehttps://www.modernatx.com/
BörsenkürzelMRNA
IPO-datumDec 07, 2018
CEOMr. Stephane Bancel
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.09%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
26.89K
+2.24%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
16.94K
+4.63%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
+46.51%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Dr. Noubar B. Afeyan, Ph.D.
Dr. Noubar B. Afeyan, Ph.D.
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Rose Loughlin
Dr. Rose Loughlin
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Jerh Collins
Mr. Jerh Collins
Chief Technical Operations and Quality Officer
Chief Technical Operations and Quality Officer
--
--
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.09%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
26.89K
+2.24%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
16.94K
+4.63%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
+46.51%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
COVID
84.00M
97.67%
RSV
2.00M
2.33%
Nach RegionUSD
Name
Umsatz
Anteil
Rest of the World
55.00M
63.95%
United States
31.00M
36.05%
Europe
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
COVID
84.00M
97.67%
RSV
2.00M
2.33%
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
10.41%
Baillie Gifford & Co.
6.45%
Fidelity Management & Research Company LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.62%
State Street Global Advisors (US)
4.60%
Other
68.54%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
10.41%
Baillie Gifford & Co.
6.45%
Fidelity Management & Research Company LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.62%
State Street Global Advisors (US)
4.60%
Other
68.54%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
40.95%
Investment Advisor/Hedge Fund
14.84%
Hedge Fund
7.44%
Corporation
4.68%
Research Firm
4.41%
Individual Investor
2.56%
Bank and Trust
2.41%
Pension Fund
1.26%
Venture Capital
1.21%
Other
20.25%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
2012
312.35M
80.76%
-23.80M
2025Q1
2127
325.75M
84.24%
-21.87M
2024Q4
2176
321.41M
83.21%
-6.67M
2024Q3
2154
311.92M
81.18%
-17.40M
2024Q2
2186
316.03M
82.47%
-13.47M
2024Q1
2203
318.24M
83.12%
-1.14M
2023Q4
2309
311.40M
81.63%
+3.41M
2023Q3
2445
301.25M
79.05%
-6.86M
2023Q2
2461
301.15M
78.90%
-7.01M
2023Q1
2466
303.08M
78.58%
-1.88M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
40.25M
10.41%
+71.93K
+0.18%
Mar 31, 2025
Baillie Gifford & Co.
24.95M
6.45%
-13.94M
-35.85%
Mar 31, 2025
Fidelity Management & Research Company LLC
20.83M
5.39%
+2.44M
+13.30%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
17.87M
4.62%
-166.51K
-0.92%
Mar 31, 2025
State Street Global Advisors (US)
17.78M
4.6%
+201.32K
+1.15%
Mar 31, 2025
Boston Biotech Ventures, L.L.C.
9.21M
2.38%
+160.31K
+1.77%
Mar 05, 2025
Two Sigma Investments, LP
8.26M
2.14%
+7.49M
+976.22%
Mar 31, 2025
Geode Capital Management, L.L.C.
7.46M
1.93%
+215.24K
+2.97%
Mar 31, 2025
Theleme Partners LLP
7.24M
1.87%
-64.47K
-0.88%
Mar 31, 2025
OCHA, L.L.C.
6.56M
1.7%
--
--
Mar 05, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Genomics Immunology and Healthcare ETF
4.09%
Global X Genomics & Biotechnology ETF
4.08%
First Trust NYSE Arca Biotechnology Index Fund
3.31%
SPDR S&P Biotech ETF
2.42%
VanEck Biotech ETF
2.35%
Virtus LifeSci Biotech Products ETF
1.94%
Langar Global HealthTech ETF
1.9%
WisdomTree BioRevolution Fund
1.66%
Invesco S&P 500 Equal Weight Health Care ETF
1.65%
ROBO Global Healthcare Technology & Innovation ETF
1.43%
Mehr Anzeigen
iShares Genomics Immunology and Healthcare ETF
Anteil4.09%
Global X Genomics & Biotechnology ETF
Anteil4.08%
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.31%
SPDR S&P Biotech ETF
Anteil2.42%
VanEck Biotech ETF
Anteil2.35%
Virtus LifeSci Biotech Products ETF
Anteil1.94%
Langar Global HealthTech ETF
Anteil1.9%
WisdomTree BioRevolution Fund
Anteil1.66%
Invesco S&P 500 Equal Weight Health Care ETF
Anteil1.65%
ROBO Global Healthcare Technology & Innovation ETF
Anteil1.43%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
